Almirall lifts nine-month sales on strong European dermatology growth
Almirall's nine-month 2026 net sales rose 8.3% and EBITDA grew 22.7%, with full-year guidance reiterated. Reported by Reuters.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Spanish biopharma Almirall said its net sales for the first nine months of 2026 rose 8.3% year on year. The main driver was its European dermatology business, where sales grew 17.6%. EBITDA for the same period increased 22.7%, with a margin of 24.9%, according to Reuters.
Sales of Ebglyss jumped 75% to €132.1 million, while Ilumetri rose 11.5% to €190.6 million. Wynzora sales climbed 15.4% to €29.3 million and Klisyri rose 18.4% to €23.8 million. The company reiterated its 2026 guidance of 9-12% net sales growth and EBITDA between €270 million and €290 million.
why it matters
For investors, the key point is that the company kept its full-year targets while EBITDA is growing faster than sales. According to LSEG data, 11 analysts rate the shares buy or strong buy, two hold, and none sell. The median 12-month price target is €14.13, versus a €11.22 close on November 6.
market impact
Almirall shares: strong sales and a reaffirmed outlook give the stock a supportive backdrop
tags
instruments
sources
- Biopharma Almirall 9M sales rise on European dermatology growth — Reuters, 9 November 2026 at 06:42 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗